Digital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
DARIOHEALTH CORP
DRIO
Current price
$0.57
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertensio...
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertension.
Teladoc Inc
TDOC
Current price
$7.52
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platf...
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platform.
Hims & Hers Health Inc
HIMS
Current price
$46.02
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfil...
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfillment.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represents the next evolution in healthcare, where FDA-cleared software serves as medicine itself. These companies create evidence-based interventions delivered directly to patients via apps and platforms, transforming treatment for chronic diseases, mental health conditions, and more.
What You Need to Know
This portfolio spans the digital health ecosystem, from specialized software developers to telehealth platforms and supportive technologies. A key catalyst is growing regulatory acceptance and new reimbursement pathways, validating both the clinical effectiveness and commercial potential of these innovations.
Why These Stocks
We've selected companies whose primary business involves creating software-based medical interventions, ensuring direct exposure to this innovative field. Many are seeing increasing insurance coverage decisions, which is critical for widespread adoption and long-term revenue growth.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+200.09%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 200.09% over the next year.
Stocks Rated Buy by Analysts
9 of 12 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Software is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases—not just track symptoms. It's an entirely new category of medicine with massive growth potential.
Insurance Companies are Paying
A major catalyst is happening right now: insurers are increasingly covering these digital treatments, unlocking billions in potential revenue that wasn't accessible before.
Early Stage with Big Backers
Major pharmaceutical companies and healthcare systems are partnering with these innovators, signaling their belief in the technology's transformative potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.